Skip to main content
. 2017 Feb 8;8(12):19285–19297. doi: 10.18632/oncotarget.15195

Figure 3. c-Myc regulates CCAT1 expression by binding to the promoter of CCAT1 in HBE cells.

Figure 3

Densities of bands were quantified by Eagle Eye II software. GAPDH levels, measured in parallel, served as controls. (A) Schematic graph illustrating binding sites of c-Myc in the promoter of CCAT1. HBE cells were exposed to CSE (0 or 20 μg/mL) in the absence or presence of 100 ppm c-Myc siRNA or control siRNA for 24 h. (B) Western blots and (C) relative protein levels (means ± SD, n = 3) of c-Myc were determined. (D) The levels (means ± SD, n = 3) of CCAT1 were determined by quantitative RT-PCR. **P < 0.05, different from CSE-treated HBE cells in the absence of the c-Myc siRNA. HBE cells were exposed to CSE (0 or 20 μg/mL) for 24 h. (E) the binding of c-Myc to promoters of CCAT1 was measured by a ChIP assay after chromatin was immunoprecipitated with an antibody against c-Myc.